NCT07081646 - A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

August 15, 2029

Study Completion Date

December 19, 2030

Conditions

Relapsed AL AmyloidosisRefractory AL AmyloidosisLight Chain AmyloidosisAmyloidosis

Interventions

DRUG

AZD0120

Participants will receive AZD0120 via intravenous (IV) infusion.

Trial Locations (11)

10032

RECRUITING

Research Site, New York

10065

NOT_YET_RECRUITING

Research Site, New York

37232

NOT_YET_RECRUITING

Research Site, Nashville

44195

NOT_YET_RECRUITING

Research Site, Cleveland

48201

NOT_YET_RECRUITING

Research Site, Detroit

55905

NOT_YET_RECRUITING

Research Site, Rochester

63110

NOT_YET_RECRUITING

Research Site, St Louis

85028

NOT_YET_RECRUITING

Research Site, Phoenix

94143

NOT_YET_RECRUITING

Research Site, San Francisco

T2N 5G2

NOT_YET_RECRUITING

Research Site, Calgary

NW3 2PF

NOT_YET_RECRUITING

Research Site, London